Mecure Industries profit growth accelerated sharply in the year ended 31 December 2025, as the pharmaceutical manufacturer posted a 177 per cent rise in profit after tax. The company reported earnings of N6.46bn, compared with N2.33bn in 2024, according to its audited financial statements.
Notably, the strong bottom-line performance followed a significant expansion in revenue. Turnover increased to N77.69bn in 2025 from N46.03bn in 2024, representing a 69 per cent year-on-year growth. As a result, the company achieved one of its strongest annual performances in recent years.
The surge in Mecure Industries profit growth reflected broad-based expansion across product categories. Revenue from the acute segment climbed to N42.57bn in 2025, up from N25.22bn in the prior year. Consequently, the acute division remained the largest contributor to total turnover.
Similarly, the over-the-counter segment delivered robust gains. OTC revenue rose to N17.31bn from N10.26bn in 2024. This performance indicates stronger consumer demand and improved distribution reach across retail markets.
In addition, supplements generated N8.70bn in sales, compared with N5.15bn a year earlier. Meanwhile, revenue from chronic products grew to N5.35bn from N3.17bn. Together, these categories reinforced the company’s diversified revenue base.
The narcotics segment also recorded growth. Sales increased to N2.52bn, up from N1.49bn in 2024. Promotional sales followed the same upward trend, rising to N1.24bn compared with N736.85m in the previous year. Therefore, every major segment contributed to the overall improvement in Mecure Industries profit growth.
On the balance sheet, the company strengthened its asset base. Total assets expanded to N81.96bn as of 31 December 2025, compared with N54.84bn in 2024. This increase reflects higher operational scale and reinvestment in production capacity.
Importantly, the audited results suggest improved operational efficiency alongside revenue expansion. Revenue growth combined with cost discipline to widen margins and lift net profitability. Consequently, shareholders stand to benefit from stronger earnings performance.
The Board of Directors recommended a dividend payout equivalent to 20 per cent of Earnings Per Share. This translates to N0.32 per share for the 2025 financial year, subject to shareholder approval. In comparison, the company paid N0.15 per share for 2024. Thus, the proposed dividend reflects confidence in sustained Mecure Industries profit growth.
Industry analysts note that Nigeria’s pharmaceutical sector has experienced increased demand due to population growth, healthcare expansion, and rising awareness of medical treatment. Against this backdrop, Mecure Industries appears to have capitalised on market opportunities while strengthening operational execution.
Furthermore, the company’s performance signals resilience within the healthcare manufacturing space. By expanding across acute, OTC, chronic, and supplement categories, Mecure has diversified risk and strengthened its competitive position. This diversification likely supported the marked rise in Mecure Industries profit growth.
Investors will also examine how the company sustains momentum into the next financial year. Continued revenue expansion, disciplined cost management, and strategic capital allocation will remain critical. In addition, maintaining product availability and distribution efficiency could further enhance earnings performance.
Overall, the audited financial statements point to a year defined by scale expansion and profitability improvement. Strong top-line growth, balanced portfolio performance, and improved margins combined to deliver substantial gains in net income. As a result, Mecure Industries profit growth stands out as one of the most notable corporate turnarounds in the sector for 2025.
